IL6 and Cognitive impairment: Baicalin (100 mg/kg) treatment for 14 days in an Aβ1-42-protein-induced mouse model can dramatically improve memory impairments in MWM and probe tests, degrade glial cell activation, and reduce inflammatory factors (IL-6 and TNF-α), revealing that baicalin improves Aβ1-42-protein-related pathological and cognitive disorder through its anti-neuroinflammatory activity [43].